Bank of New York Mellon’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $559K | Buy |
57,262
+45,863
| +402% | +$398K | ﹤0.01% | 3693 |
|
|
2026
Q1 | $63.5K | Buy |
11,399
+312
| +3% | +$2.38K | ﹤0.01% | 4131 |
|
|
2025
Q4 | $81.6K | Buy |
11,087
+1
| +0% | +$6 | ﹤0.01% | 4115 |
|
|
2025
Q3 | $72.5K | Hold |
11,086
| – | – | ﹤0.01% | 4114 |
|
|
2025
Q2 | $47.8K | Hold |
11,086
| – | – | ﹤0.01% | 4089 |
|
|
2025
Q1 | $41.5K | Sell |
11,086
-2
| -0% | -$17 | ﹤0.01% | 4062 |
|
|
2024
Q4 | $112K | Hold |
11,088
| – | – | ﹤0.01% | 4023 |
|
|
2024
Q3 | $138K | Hold |
11,088
| – | – | ﹤0.01% | 3971 |
|
|
2024
Q2 | $144K | Sell |
11,088
-21,383
| -66% | -$354K | ﹤0.01% | 3992 |
|
|
2024
Q1 | $735K | Sell |
32,471
-676
| -2% | -$11.9K | ﹤0.01% | 3313 |
|
|
2023
Q4 | $430K | Sell |
33,147
-10,430
| -24% | -$141K | ﹤0.01% | 3634 |
|
|
2023
Q3 | $876K | Sell |
43,577
-464
| -1% | -$10.4K | ﹤0.01% | 3233 |
|
|
2023
Q2 | $1.18M | Buy |
44,041
+13,743
| +45% | +$592K | ﹤0.01% | 3103 |
|
|
2023
Q1 | $1.77M | Buy |
30,298
+1,439
| +5% | +$71K | ﹤0.01% | 2867 |
|
|
2022
Q4 | $1.47M | Buy |
28,859
+8,926
| +45% | +$619K | ﹤0.01% | 3009 |
|
|
2022
Q3 | $1.63M | Buy |
19,933
+841
| +4% | +$62.8K | ﹤0.01% | 2961 |
|
|
2022
Q2 | $1.29M | Sell |
19,092
-701
| -4% | -$64.3K | ﹤0.01% | 3077 |
|
|
2022
Q1 | $2.19M | Sell |
19,793
-43
| -0.2% | -$5.36K | ﹤0.01% | 2881 |
|
|
2021
Q4 | $1.91M | Sell |
19,836
-331
| -2% | -$33K | ﹤0.01% | 3024 |
|
|
2021
Q3 | $1.76M | Buy |
20,167
+897
| +5% | +$93.1K | ﹤0.01% | 3059 |
|
|
2021
Q2 | $2.98M | Sell |
19,270
-2,047
| -10% | -$297K | ﹤0.01% | 2753 |
|
|
2021
Q1 | $3.37M | Sell |
21,317
-614
| -3% | -$129K | ﹤0.01% | 2637 |
|
|
2020
Q4 | $5.09M | Sell |
21,931
-1,170
| -5% | -$271K | ﹤0.01% | 2348 |
|
|
2020
Q3 | $5.06M | Buy |
23,101
+1,767
| +8% | +$432K | ﹤0.01% | 2210 |
|
|
2020
Q2 | $6.06M | Sell |
21,334
-495
| -2% | -$146K | ﹤0.01% | 2121 |
|
|
2020
Q1 | $6.29M | Buy |
21,829
+2,423
| +12% | +$668K | ﹤0.01% | 1959 |
|
|
2019
Q4 | $5.58M | Buy |
19,406
+3,387
| +21% | +$735K | ﹤0.01% | 2282 |
|
|
2019
Q3 | $2.31M | Buy |
16,019
+576
| +4% | +$78.1K | ﹤0.01% | 2673 |
|
|
2019
Q2 | $1.39M | Buy |
15,443
+844
| +6% | +$67.8K | ﹤0.01% | 3013 |
|
|
2019
Q1 | $1.28M | Buy |
14,599
+38
| +0.3% | +$4.21K | ﹤0.01% | 3020 |
|
|
2018
Q4 | $2.05M | Sell |
14,561
-12
| -0.1% | -$2.02K | ﹤0.01% | 2712 |
|
|
2018
Q3 | $3.72M | Buy |
14,573
+305
| +2% | +$84.3K | ﹤0.01% | 2537 |
|
|
2018
Q2 | $3.64M | Buy |
14,268
+3,128
| +28% | +$774K | ﹤0.01% | 2547 |
|
|
2018
Q1 | $2.24M | Buy |
11,140
+267
| +2% | +$53.2K | ﹤0.01% | 2746 |
|
|
2017
Q4 | $1.57M | Sell |
10,873
-48
| -0.4% | -$7.71K | ﹤0.01% | 2989 |
|
|
2017
Q3 | $1.8M | Buy |
10,921
+76
| +0.7% | +$10.9K | ﹤0.01% | 2898 |
|
|
2017
Q2 | $1.47M | Sell |
10,845
-1,262
| -10% | -$187K | ﹤0.01% | 3027 |
|
|
2017
Q1 | $2.33M | Buy |
12,107
+4,621
| +62% | +$742K | ﹤0.01% | 2761 |
|
|
2016
Q4 | $1.06M | Buy |
7,486
+1,632
| +28% | +$221K | ﹤0.01% | 3229 |
|
|
2016
Q3 | $854K | Sell |
5,854
-917
| -14% | -$110K | ﹤0.01% | 3258 |
|
|
2016
Q2 | $682K | Buy |
6,771
+279
| +4% | +$36.2K | ﹤0.01% | 3379 |
|
|
2016
Q1 | $869K | Sell |
6,492
-461
| -7% | -$50.9K | ﹤0.01% | 3147 |
|
|
2015
Q4 | $1.38M | Sell |
6,953
-14
| -0.2% | -$3.03K | ﹤0.01% | 2945 |
|
|
2015
Q3 | $1.1M | Sell |
6,967
-587
| -8% | -$157K | ﹤0.01% | 3126 |
|
|
2015
Q2 | $3.08M | Buy |
7,554
+2,144
| +40% | +$927K | ﹤0.01% | 2643 |
|
|
2015
Q1 | $2.48M | Buy |
5,410
+1,208
| +29% | +$521K | ﹤0.01% | 2710 |
|
|
2014
Q4 | $2.36M | Buy |
4,202
+10
| +0.2% | +$5.68K | ﹤0.01% | 2763 |
|
|
2014
Q3 | $2.2M | Buy |
4,192
+1,027
| +32% | +$580K | ﹤0.01% | 2814 |
|
|
2014
Q2 | $2.21M | Sell |
3,165
-489
| -13% | -$228K | ﹤0.01% | 2855 |
|
|
2014
Q1 | $1.69M | Buy |
3,654
+1,858
| +103% | +$942K | ﹤0.01% | 2981 |
|
|
2013
Q4 | $617K | Buy |
+1,796
| New | +$496K | ﹤0.01% | 3505 |
|
Other funds holding KPTI
SCM
CWG
N
CUAMC
Bank of New York Mellon's KPTI Position: Q2 2026 in Review
Bank of New York Mellon increased its Karyopharm Therapeutics (KPTI) stake by 402% in Q2 2026, buying an estimated $398K and bringing the position to 57,262 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #3693.
Bank of New York Mellon first reported a position in KPTI in Q4 2013 and has held it in 51 quarters since. The position peaked at $6.29M in Q1 2020. 32 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.
- Bank of New York Mellon held 57,262 shares of Karyopharm Therapeutics worth $559K as of Q2 2026.
- Bank of New York Mellon bought 45,863 Karyopharm Therapeutics shares in Q2 2026, an estimated $398K.
- Karyopharm Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3693 holding.
- Bank of New York Mellon first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 51 quarters since.
- Bank of New York Mellon's Karyopharm Therapeutics position peaked at $6.29M in Q1 2020.
- 32 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.